DISCONTINUED OPERATIONS - Narrative (Details) - RX Pharmaceuticals - Discontinued Operations, Disposed of by Sale $ in Millions |
Jul. 06, 2021
USD ($)
|
|---|---|
| Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |
| Total consideration in definitive agreement to sell | $ 1,550.0 |
| Potential R&D milestone payments and contingent purchase obligations assumed by purchaser | $ 53.3 |
| Supply agreement term | 4 years |
| Supply agreement, extension period | 7 years |
| Aggregate cap on buyer's obligation for certain pre-closing liabilities (percent) | 50.00% |
| Aggregate cap on buyer's obligation for certain pre-closing liabilities | $ 50.0 |